

Haematologica
HAEMATOL/2018/190157
Version 4

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2
and/or BCL6 rearrangements is not associated with MYC/IG gene
rearrangements

Ellen D. McPhail, Matthew J. Maurer, William R. Macon, Andrew L.
Feldman, Paul J. Kurtin, Rhett P. Ketterling, Rakhee Vaidya, James R.
Cerhan, Stephen M. Ansell, Luis F. Porrata, Grzegorz S. Nowakowski,
Thomas E. Witzig, and Thomas M. Habermann

Disclosures: This work was supported in part by National Institutes of Health (NIH) Grant No. P50 CA97274 to the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence, National Cancer Institute (NCI) Grant No. R01 CA200703, NCI Grant No. U01 CA195568, and the Henry J. Predolin Foundation, Inc. Conflict of interest disclosure: G.S.N. receives research support from Celgene, Roche, MorphoSys, and Bayer and serves on advisory boards for Celgene, Bayer, MorphoSys, and AbbVie. The other authors declare no competing financial interests

Contributions: E.D.M., T.E.W., and T.M.H. participated in the conception and design of the study; J.R.C., T.E.W., and T.M.H. participated in administrative support; E.D.M., W.R.M., A.L.F., P.J.K., R.P.K., R.V., and T.M.H. participated in the collection of data; E.D.M., M.J.M., R.P.K., and T.M.H. participated in the analysis and interpretation of data; E.D.M., M.J.M., W.R.M., A.L.F., P.J.K., R.P.K., R.V., J.R.C., S.M.A., L.F.P., G.S.N., T.E.W., and T.M.H. wrote the manuscript and gave final approval.